Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US9708393B2 · kind B2 · utility
18Cited by
25References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2012 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | May 21, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.